Access to the right medicines is an important component in managing arthritis. In Canada, the Patented Medicines Prices Review Board (PMPRB) plays a key role in drug pricing in Canada. On July 1, 2020, the newly amended Patented Medicines Regulations will come into...
Chronic pain is something that many individuals living with arthritis deal with on an on-going basis. CAPA has been very involved in the work of the Canadian Pain Task Force announced in April 2019, with Linda Wilhelm, CAPA President, named as a member of the Task...
In April 2019, The Hospital for Sick Children (SickKids) in Toronto shut down its Motherisk program. The Motherisk program, initially established in 1985, provided information on the safety of medications and substances during pregnancy. In May, the Society of...
In July 2019, Health Canada began a 60-day consultation on the draft guidance: The Distinction Between Promotional and Non-promotional Messages and Activities for Health Products, formerly known as a policy entitled The Distinction Between Advertising and Other...
Bill C-17 amends the Food and Drugs Act, which hasn’t been substantially updated in over 50 years. It was introduced to the House of Commons by the Minister of Health in December 2013. The Bill has two main goals: Strengthen safety oversight of therapeutic products...
English 
Français du Canada